| CAS NO: | 475207-59-1 |
| 规格: | ≥98% |
| 包装 | 价格(元) |
| 250mg | 电议 |
| 500mg | 电议 |
| 1g | 电议 |
| 2g | 电议 |
| 5g | 电议 |
| 10g | 电议 |
| 25g | 电议 |
| 50g | 电议 |
| Molecular Weight (MW) | 637.03 |
|---|---|
| Formula | C21H16ClF3N4O3.C7H8O3S |
| CAS No. | 475207-59-1(tosylate); |
| Storage | -20℃ for 3 years in powder form |
| -80℃ for 2 years in solvent | |
| Solubility (In vitro) | DMSO: 127 mg/mL (199.4 mM) |
| Water: <1 mg/mL (slightly soluble or insoluble) | |
| Ethanol: <1 mg/mL | |
| Synonym | BAY 43-9006 tosylate; BAY549085; BAY-439-006; BAY 549085; BAY-439006 tosylate; BAY 439006; BAY439006 tosylate; BAY-549085; Nexavar; SFN. |
| General | Oral administration of Sorafenib tosylate (~60 mg/kg) demonstrates broad spectrum, dose-dependent anti-tumor activity against a variety of human tumor xenograft models including MDA-MB-231, Colo-205, HT-29, DLD-1, NCI-H460, and A549, with no evidence of toxicity. |
|---|---|
| Animal model | Female NCr-nu/nu mice implanted s.c. with MDA-MB-231, Colo-205, HT-29, H460, or A549 cells |
| Formulation | Cremophor EL/ethanol (1:1) as 4-fold (4 × stock solution), and diluted to 1 × with w |
| Dosages | 60 mg/kg |
| Administration | Administered orally once a day |
| Reference | [1] Wilhelm SM, et al. Cancer Res, 2004, 64(19), 7099-7109. |
|  |
The number of nuclei breaking the internal limiting membrane (ILM). A: Controlled group; B: ROP group; C: Vehicle-treated ROP group; D: Low doses sorafenib-treated ROP group; E: Middle doses sorafenib-treated ROP group; F: High dose sorafenib-treated ROP group. |
m.cnreagent.com
